Although ICB may potentially benefit certain subsets of patients with recurrent glioma [17–19], a randomized phase III study of PD-1/PD-L1 axis inhibition for GBM did not demonstrate prolonged overall survival [20]. This evidence concerns the gene PDCD1 and glioma.